Pateclizumab
- Generic Name
- Pateclizumab
- Drug Type
- Biotech
- CAS Number
- 1202526-59-7
- Unique Ingredient Identifier
- QOK1YYH7J2
- Background
Pateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis).
A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2010-10-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 211
- Registration Number
- NCT01225393
A Study of the Safety and Pharmacokinetics of PRO283698 in Patients With Rheumatoid Arthritis
- First Posted Date
- 2009-04-28
- Last Posted Date
- 2010-12-01
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT00888745
- Locations
- 🇭🇺
Investigational Site, Szeged, Hungary
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath